Evaluating Safety & Toxicity Packages for Marketed & Late-Stage Clinical Investigational Drugs
Time: 9:15 am
day: Focus Day
Details:
- Highlighting the safety and toxicity packages which are made to advance safe small molecules targeting RNA towards the patients in need
- Evaluating the safety window which is required for regulatory approval to fast-track RNA-targeting therapeutics towards the clinic
- Uncovering reliable preclinical models used to represent RNA targets and analyse small molecule safety
